Therapeutic compound and treatments
View Patent ↗Compositions and uses associated with the MT477 family of compounds are disclosed. Particular structural features and properties of the compounds are described in detail. Uses include administering an MT477 family member to a patient for therapeutic purposes. Compositions include chemicals belonging to the MT477 family and pharmaceuticals that contain such chemicals.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of formula 3 (a)
or a pharmaceutically acceptable salt thereof; wherein
Z is a linking group;
A 1 , A 2 , A 3 , A 5 , A 6 , A 8 , A 9 , A 10 , A 11 , A 14 , and Y 1 -Y 5 are each independently selected from C, S, O, P or N; and
each R 1 -R 8 and T 1 -T 14 are independently chosen to be vacant,
or a group that is a lone electron pair, a bond, a pi bond, H, a halogen, a hydroxyl group, a thiol group, a sulfonate group, a carboxyl group, an amino group, an amido group, an amide group, a phosphate group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an oxo group, an ether, an ester, a ketone, a carboxyl, a cyclic group, an alicyclic group, a heterocyclic group, or an aromatic group.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of formula 4 (c)
or a pharmaceutically acceptable salt thereof; wherein
each X is independently selected from O, N, S, or P;
each Q and Q 1 -Q 4 are independently N or C; and each R 1 -R 11 are independently selected from halogen, R′, OR′, hydroxyl group, SR′, thiol group, N(R′) 2 , SO 2 R′, OSO 2 R′, NR′(CO)R′, (CO)N(R′) 2 , O(CO)N(R′) 2 , amino group, a 3-7 member saturated, partially unsaturated, or aryl ring having 0-2 heteroatoms independently selected from N, O or S; wherein each R′ is independently selected from H, an optionally saturated C 1 -C 6 aliphatic group, 3-8 member saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from N, O or S.
3. A pharmaceutical composition of claim 1 , wherein the compound has a structure selected from
or a pharmaceutically acceptable salt thereof.
4. A method of treating leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer or pancreatic cancer, comprising administering to a patient in need thereof a compound of formula 3 (a)
or a pharmaceutically acceptable salt thereof; wherein
Z is a linking group;
A 1 , A 2 , A 3 , A 5 , A 6 , A 8 , A 9 , A 10 , A 11 , A 14 , and Y 1 -Y 5 are each independently selected from C, S, O, P or N; and
each R 1 -R 8 and T 1 -T 14 are independently chosen to be vacant,
or a group that is a lone electron pair, a bond, a pi bond, H, a halogen, a hydroxyl group, a thiol group, a sulfonate group, a carboxyl group, an amino group, an amido group, an amide group, a phosphate group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an oxo group, an ether, an ester, a ketone, a carboxyl, a cyclic group, an alicyclic group, a heterocyclic group, or an aromatic group.
5. A method of treating leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer or pancreatic cancer, comprising administering to a patient in need thereof a compound of formula 4 (c)
or a pharmaceutically acceptable salt thereof; wherein
each X is independently selected from O, N, S, or P;
each Q and Q 1 -Q 4 are independently N or C; and each R 1 -R 11 are independently selected from halogen, R′, OR′, hydroxyl group, SR′, thiol group, N(R′) 2 , SO 2 R′, OSO 2 R′, NR′(CO)R′, (CO)N(R′) 2 , O(CO)N(R′) 2 , amino group, a 3-7 member saturated, partially unsaturated, or aryl ring having 0-2 heteroatoms independently selected from N, O or S; wherein each R′ is independently selected from H, an optionally saturated C 1 -C 6 aliphatic group, 3-8 member saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from N, O or S.
6. A method of treating leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer or pancreatic cancer, comprising administering to a patient in need thereof a compound comprising a structure selected from
or a pharmaceutically acceptable salt thereof.
7. The method of any one of claims 4 - 6 , wherein the cancer is non-small cell lung cancer.
8. The method of any one of claims 4 - 6 , wherein the cancer is pancreatic cancer.
9. A method of treating leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer or pancreatic cancer, comprising administering to a patient in need thereof a pharmaceutical composition of claim 1 or 2 .